Empowered Funds LLC acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 59,848 shares of the company’s stock, valued at approximately $8,979,000.
Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after acquiring an additional 435,232 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after acquiring an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after purchasing an additional 72,162 shares in the last quarter. 92.60% of the stock is owned by institutional investors.
Guardant Health Trading Down 4.2%
GH stock opened at $161.50 on Friday. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58. The company has a 50-day moving average price of $157.49 and a 200 day moving average price of $120.75. The stock has a market cap of $21.67 billion, a PE ratio of -46.27 and a beta of 1.60.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. UBS Group set a $150.00 price objective on shares of Guardant Health in a research note on Wednesday, June 24th. Evercore restated an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a report on Monday, July 6th. Royal Bank Of Canada increased their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, BTIG Research lifted their price target on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $183.78.
Check Out Our Latest Analysis on GH
Insider Transactions at Guardant Health
In related news, insider Terilyn J. Monroe sold 46,300 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider owned 22,979 shares in the company, valued at $3,794,292.48. The trade was a 66.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Chris Freeman sold 63,605 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the transaction, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. This trade represents a 49.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 548,318 shares of company stock valued at $82,501,873. Company insiders own 5.60% of the company’s stock.
About Guardant Health
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Articles
- Five stocks we like better than Guardant Health
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
